Slashj, you are right for overall CRC this is about 15-20%, but these tumours have a better prognosis and are less likely to develop mets, 4% rate in mCRC population.
- Forums
- ASX - By Stock
- SRX
- Immunotherapy
Immunotherapy, page-6
Featured News
Add SRX (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online